Clinical application of Imaging Mass-spectrometry in cancer fileld

• Project/Area Number: 15K14398
• Research Category: Grant-in-Aid for Challenging Exploratory Research
• Allocation Type: Multi-year Fund
• Research Field: Tumor diagnostics
• Research Institution: Keio University
• Principal Investigator: Yasuda Hiroyuki 慶應義塾大学, 医学部(信濃町), 講師 (70365261)
• Project Period (FY): 2015-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 癌 / 血管新生阻害薬 / 代謝 / Mass-spectrometry / 肺癌 / 癌細胞の代謝 / 抗癌剤

Outline of Final Research Achievements

The prognosis of cancer patients is poor. To improve the prognosis of cancer patients, variable approaches are necessary. Imaging mass-spectrometry (IMS) is a novel technology, which enables one to viisualize the distribution of hundreds of metabloite in tissues. Using this novel technology, we treid to clarify the mechansims of efficacy of some anti-cancer agents. We focused on anti-angiogenic agents such as nintedanib or bevacizumab. We partly clarified the mechanisms of efficacy of these agents by in vivo experiments with IMS. The findings will help developing an effective and appropriate treatement using anti-angiogenic agents.

Research Products

• [Journal Article] Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. (2017)
  • Author(s): Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, Goto K, Betsuyaku T, Soejima K.
  • Journal Title: Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ Volume: 77（８） Issue: 8 Pages: 2078-2089
  • DOI: 10.1158/0008-5472.can-16-2359
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. (2017)
  • Author(s): Miyawaki M, Yasuda H, Tani T, Hamamoto J, Arai D, Ishioka K, Ohgino K, Nukaga S, Hirano T, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.
  • Journal Title: Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ Volume: 15(1） Issue: 1 Pages: 106-114
  • DOI: 10.1158/1541-7786.mcr-16-0211
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib (2016)
  • Author(s): Tani T, Yasuda H, Hamamoto J, Kuroda A, Arai D, Ishioka K, Ohgino K, Miyawaki M,, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K
  • Journal Title: Molecular Cancer Therapeutics Volume: 15(1) Issue: 1 Pages: 162-71
  • DOI: 10.1158/1535-7163.mct-15-0084
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer (2016)
  • Author(s): Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, BetsuyakuT, Soejima K
  • Journal Title: Oncotarget Volume: 17 Issue: 36 Pages: 38789-803
  • DOI: 10.18632/oncotarget.5887
  • Peer Reviewed / Open Access / Int'l Joint Research / Acknowledgement Compliant